Compare FC & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FC | SGMT |
|---|---|---|
| Founded | 1983 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.5M | 169.4M |
| IPO Year | 1994 | 2021 |
| Metric | FC | SGMT |
|---|---|---|
| Price | $15.22 | $4.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $26.00 | ★ $26.38 |
| AVG Volume (30 Days) | 169.1K | ★ 321.0K |
| Earning Date | 04-01-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $267,067,000.00 | $2,000,000.00 |
| Revenue This Year | $3.02 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.16 | $1.73 |
| 52 Week High | $28.39 | $11.41 |
| Indicator | FC | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 62.50 | 38.78 |
| Support Level | $14.04 | N/A |
| Resistance Level | $20.33 | $6.62 |
| Average True Range (ATR) | 0.71 | 0.30 |
| MACD | 0.62 | -0.03 |
| Stochastic Oscillator | 87.40 | 7.35 |
Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.